4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Asthma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 992 ongoing clinical trials involving Asthma
Of the 992 trials,304 trials are in Phase III
Furthermore, 279 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Asthma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Asthma, a Respiratory condition. The highest number of ongoing clinical trials involving Asthma is in Asia-Pacific. Europe and North America are among some of the other prominent regions involved in Asthma-related drug trials.

AstraZeneca Plc: The leading ongoing Asthma-related clinical trials sponsor

AstraZeneca Plc, the UK-based Pharmaceutical company, is the top sponsor for Asthma-related ongoing clinical trials.

GlaxoSmithKline Plc, Sanofi, Novartis AG, Inmunotek SL, and Bispebjerg Hospital are a few other notable sponsors involving Asthma.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Asthma

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis), Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte), and Tiotropium bromide (Spiriva/ Spiriva Respimat/ Favint/ Favint Respimat/ Favynd/ Srivasso, Spiriva Handihaler) are among the key marketed drugs involving Asthma.

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody developed based on VelocImmune technology. It functions via the Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist. It is formulated as an injectable solution and injectable powder for solution for subcutaneous route of administration. Dupilumab is indicated for the treatment of moderate to severe atopic dermatitis (eczema) in adults, in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupilumab was first approved in 2017 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including Sanofi-Aventis US LLC.

Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte) is a fixed dose combination drug, acts as an anti-inflammatory and bronchodilator agent. It functions via Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Agonist; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as an aerosol, powder, suspension for an inhalational route of administration. It is indicated in the regular treatment of asthma where the use of a combination (inhaled corticosteroid and long-acting beta-2 adrenoceptor agonist) is appropriate. Budesonide and formoterol fumarate was first approved in 2000 and is marketed globally including the US, the UK, France, Germany, and Japan by several prominent pharma giants including AstraZeneca Plc.